The prevalence of severe asthma is thought to affect 5% to 10% of the total asthmatic population. 1 An analysis of patients with uncontrolled persistent allergic asthma who commenced omalizumab treatment within the previous 15 weeks showed that approximately 29% of these patients were also receiving oral corticosteroids (OCSs). 2 In 30% of adults with severe asthma, OCSs are required in addition to inhaled corticosteroids (ICSs) to maintain some degree of asthma control. 1 Although OCSs might be required for patients with severe uncontrolled asthma, they are associated with serious adverse effects (AEs). AEs of long-term exposure to OCSs include osteoporosis, arterial hypertension, diabetes and metabolic syndrome, dyslipidemia, obesity, cataracts, glaucoma, gastrointestinal bleeds/ulcers, tuberculosis, depression, herpes, and sepsis. 3, 4 Indeed, asthma guidelines recommend that patients taking long-term systemic OCSs should receive preventive treatment for osteoporosis. 3 Numerous studies have documented the association between OCS use and long-term development of AEs in a variety of conditions in nonasthmatic populations. 4 Within asthmatic populations, Lefebvre et al 5 provide preliminary evidence that higher doses and continuous exposure to OCSs were associated with increased risk of AEs. Little is known about AEs associated with bursts of OCSs or lower-dose treatment in asthmatic patients. More information is needed to understand the relationship between OCS exposure and the development of long-term AEs in asthmatic patients.
There are limited treatment options available for severely uncontrolled asthma in the last steps of treatment. Given the prevalent use of OCSs in patients with severe asthma, as well as the incidence of OCS-related AEs, it is important to characterize the AEs associated with OCS treatment in asthmatic patients so as to more robustly understand the comparative risks. The objective of this research is to examine the association between the number of OCS prescriptions and the incidence of AEs in asthmatic patients.
METHODS
This was a retrospective cohort study of asthmatic patients in an insurance claims data set (MarketScan Claims Database). AEs associated with OCS use are relatively uncommon events and develop over time. Hence a large population with multiple years of data is preferable to capture adequate numbers of events over time. MarketScan is an existing database with multiple years of data and a very large sample of asthmatic patients.
Data source
The data source is the MarketScan Claims Database inclusive of January 1, 2000, to June 30, 2014. The MarketScan Databases capture person-specific clinical use, expenditures, and enrollment across inpatient, outpatient, prescription drug, and carve-out services from a selection of large employers, health plans, and government and public organizations. These data represent the medical experience of insured employees and their dependents for active employees, early retirees, COBRA recipients, and Medicare-eligible retirees with employer-provided Medicare supplemental plans. Collectively, the databases incorporate data from approximately 100 payers, including commercial insurance companies, Blue Cross and Blue Shield plans, and third-party administrators.
Study design and patient selection
A study schema is provided in Fig 1. Asthmatic patients aged 18 years and older with continuous enrollment for 12 months or more before and 24 months or more after the index date were eligible. Asthma was identified as follows:
(1) a diagnosis in at least 2 outpatient claims with primary or secondary diagnoses of asthma (International Classification of Diseases, Ninth Edition [ICD-9], code 493.xx), at least 1 of which must have been during the baseline period, or (2) at least 1 emergency department or hospitalization claim with a primary diagnosis of asthma during the baseline period. 6 Patients with any diagnosis of chronic obstructive pulmonary disease, chronic bronchitis, emphysema, or cystic fibrosis were excluded. Patients with any of the selected AEs during the baseline period (preindex, 12 months) were also excluded (AEs are discussed below and listed in Table E1 in this article's Online Repository at www.jacionline.org). Subjects in the no OCS cohort with any OCS prescriptions in the 12 months before the index date (baseline) were excluded (1-year OCS washout period). In addition, subjects in the no OCS cohort had no OCS exposure during the study follow-up.
The index date was defined differently for the OCS and no OCS cohorts. For the OCS cohort, the index date was defined as the first prescription for OCS in the study period. For the no OCS cohort, the definition of an index date was more challenging but necessary to provide comparability. Hence subjects in the no OCS cohort were randomly assigned an index date (based on a uniform distribution) based on the following requirements. To ensure adequate (24-month) follow-up, the index date was required to fall before the final 24 months of data capture for the subjects. To ensure a 12-month wash-out period, the index date was required to fall after the first 12 months of data capture. This allowed for 12 months of baseline data before the index date and at least 24 months of follow-up data. Baseline was defined as 12 months before the index date. 6 
AEs
A list of AEs associated with OCSs was derived from previously published studies in patients with asthma and other conditions. [3] [4] [5] 7 AEs and associated ICD-9 codes are listed in Table E1 and included as follows: osteoporosis, metabolic syndrome, hypertension, obesity, type 2 diabetes mellitus, cataracts, avascular necrosis, dyslipidemia, gastrointestinal ulcers/bleeds, fractures, tuberculosis, and glaucoma. These AEs develop over time and are generally considered chronic conditions. Although some AEs (eg, gastrointestinal ulcers/bleeds) can also present as acute conditions, they are often associated with long-term use. The ICD-9 diagnostic codes listed in Table E1 were derived from previous published research, 8 as well as input from 2 allergists/pulmonologists. AEs were included if they were reported with any associated claim with a primary or secondary ICD-9 diagnosis code.
Statistical analysis
The proposed outcomes (incidence of AEs) were compared between the treatment (OCS cohort) and control (no OCS cohort) groups in the follow-up period. As reflected in Global Initiative for Asthma guidelines, asthmatic patients taking OCSs are likely to have more severe and poorly controlled disease than those not taking OCSs. Previous studies have shown that patients adding/switching to OCSs are sicker and have more asthma exacerbations and higher costs than patients managing their asthma symptoms without OCS use. These differences can overestimate any potential increase in AEs because of the use of OCSs if the outcomes proposed between the treatment and control groups are compared without matching. Therefore we used propensity matching to pair each patient in the OCS group with a similar (based on matching variables) patient in the control group. Emphasis was placed on variables that could be markers of asthma control, asthma severity, and general poor health to balance any differences in the OCS and no OCS cohorts. Matching was based on values of the following in the baseline period: age, sex, number of asthma-related emergency department visits (primary diagnosis), number of asthma-related inpatient visits (primary diagnosis), short-acting b-agonist use indicating poor control (> _7 canisters in 12 months [yes/no]), 9 and comorbidity burden. Propensity score matching was conducted by using one-to-one nearest neighbor matching without replacement to select the patients in the no OCS cohort. 10, 11 After propensity score matching, other confounding characteristics were adjusted for in the statistical analyses.
Outcomes included the incidence of any (> _1) of the OCS-related adverse events listed above (combined end point) or incidence of any individual AE. Subjects were censored after experiencing the first AE (any AE resulted in censoring for all subsequent analyses of all AEs). This allowed estimation of the effect of OCS use on new-incident AEs. Each year was calculated as 12 months after the index date. Follow-up continued for a minimum of 24 months and a maximum of 10 years after the index date. Regression analyses compared the OCS cohort with the no OCS cohort (the no OCS cohort was the reference group in all regressions). For the OCS cohort, exposure was separated into current and past exposure. Current and past exposure are defined with reference to the occurrence of an AE: current is defined as taking place within the year of the AE occurrence, and past is defined as taking place in any year before occurrence of the AE.
Two regression specifications incorporating current and previous annual OCS exposure were used. Specification 1 was defined as current OCS use separated into 3 categories: (1) 4 or more prescriptions for OCSs in the current year; (2) 1 to 3 current OCS prescriptions; and (3) no current OCS prescriptions (the reference group in this case is the no OCS group). Previous OCS use was separated into 2 categories: (1) the number of previous years in which 4 or more prescriptions for OCS were used in the past (before the current year) and (2) the number of previous years in which 1 to 3 OCS prescriptions were used in the past (before the current year). Specification 2 was defined as current and past use separated into 2 categories: (1) the number of years in which 4 or more prescriptions for OCS have been used (including the current year) and (2) the number of years in which 1 to 3 OCS prescriptions have been used (including the current year).
Logistic regression was conducted for new incidence of AEs on OCS exposure, adjusting for covariates. Covariates in the regression analyses included age, sex, geographic region, years since index date, insurance type, use of immunosuppressive medication (yes/no; non-OCS), and general comorbidity burden. Comorbidity burden was defined as the total number of chronic conditions (excluding asthma [NCC] ) excluding asthma by ICD-9 code in the baseline year. 6, 12 NCC was included as several dichotomous variables in the regressions (NCC 5 1, NCC 5 2, ., NCC 5 6, NCC > _ 7; NCC 5 0 was the reference group).
RESULTS
There were 72,063 subjects meeting the criteria for the OCS cohort and 156,373 subjects meeting the criteria for the no OCS cohort before matching. Table I shows the descriptive statistics of the variables used in one-to-one propensity score matching before and after matching. Matching resulted in a balanced sample with no statistically significant difference in baseline characteristics except for asthma-related inpatient visits. Baseline study characteristics (after matching) of other covariates are displayed in Table II . As is common in asthmatic patients, the sample was relatively young (age 38 years) and predominantly female (66%) with 1.24 chronic conditions (other than asthma). Approximately 1% of both cohorts were using some prescription drug for autoimmune indications. The most common comorbidity was allergic rhinitis (31% in the no OCS and 26% in the OCS cohorts). The distribution of follow-up by cohort is shown in Table E2 in this article's Online Repository at www.jacionline.org. Table III presents adjusted regression results of the odds of having any new AE (combined end point) based on 2 different regression specifications. Subjects taking 4 or more prescriptions within the current year had 1.29 times the odds of experiencing a new AE within that year than those in the no OCS cohort, controlling for previous exposure and other covariates. Likewise, those using 1 to 3 prescriptions had 1.04 times the odds of having a new AE in the current year. The odds of experiencing a new AE in the current year were 1.10 and 1.11 times higher for each year of prior exposure to 1 to 3 and 4 or more OCS prescriptions, respectively. In the second specification each year of exposure to 4 or more OCS prescriptions (current and past) resulted in 1.20 times the odds of having an AE in the current year. For example, those who were exposed to 4 or more OCS prescriptions for 3 years in the previous decade had 1.73 higher odds (ie, exp [ln(1.2)*3] 5 1.23 5 1.73) of having a new AE compared with the no OCS cohort. Each year of exposure to 1 to 3 prescriptions resulted in 1.07 times the odds of having a new AE in the current year.
The incidence of individual AEs was also explored in Fig 2 and  Table IV . Exposure to 4 or more OCS prescriptions in the current year was associated with statistically significantly greater odds of having an AE in that year for the following: osteoporosis, hypertension, obesity, type 2 diabetes, gastrointestinal ulcers/ bleeds, fractures, and cataracts. Odds ratios ranged from 1.21 to 1.44 depending on the AE. Other AEs were not statistically significantly associated with current OCS exposure: metabolic syndrome, dyslipidemia, tuberculosis, and glaucoma (data not shown). Previous exposure to OCSs was also associated with increased odds of having a new AE in the current year for osteoporosis, hypertension, obesity, diabetes mellitus, dyslipidemia, and fractures. For example, taking 4 or more prescriptions of OCSs in the current year was associated with 1.44 higher odds of osteoporosis compared with the no OCS cohort, and taking 4 or more prescriptions of OCSs for 3 years in the previous decade was associated with an increase in the odds of having osteoporosis of 1.89 (exp[ln(1.236)*3] 5 1.89) compared with the no OCS cohort.
DISCUSSION
The results of this research suggest that exposure to OCSs and in particular intermittent use of OCSs consistent with bursts increases the odds of having an AE in a sample of asthmatic patients. The incidence of AEs appeared to increase with each year of exposure, particularly to 4 or more prescriptions of OCSs per year. Although previous research has documented the deleterious effect of continuous OCS use in patients with severe asthma, our results appear to suggest that each prescription for an OCS might result in a cumulative burden on current and future health, regardless of dose and duration.
Our results have important clinical ramifications. It appears that the number of prescriptions dispensed within a year is strongly associated with AEs, irrespective of dose and duration. The cutoff used in this research was 4 prescriptions within a year without regard to dose or duration. The results highlight the importance of maintaining asthma control and might support the notion that the use of OCS bursts is deleterious to the patient's health, even if they are short-term bursts, particularly if the patient requires more than 4 per year. In addition, this research suggests that each year of exposure to any OCS prescription results in a higher subsequent likelihood of AEs. Although the magnitude of the odds ratio was highest for exposure to 4 or more prescriptions per year, exposure to 1 to 3 OCS prescriptions per year was also statistically significantly associated with the development of current and future AEs. Treatments and disease management interventions that promote asthma control and prevent the use of OCSs, particularly 4 or more prescriptions in a year, are extremely important to improving patient outcomes.
Lefebvre et al 5 found that higher doses of OCSs were associated with increased risk of AEs in patients with severe asthma. Our study results are consistent with those of Lefebvre et al but add novel information about the relationship between OCS exposure and AEs in a different population using alternative definitions of exposure that are less likely to exclude OCS bursts and shorter duration continuous use. Lefebvre et al used an open-cohort observational study to compare continuous daily use of low-, medium-, and high-dose OCS exposure for 1 year or more (<6, >6-12, and >12 mg/d prednisone equivalent) with no control cohort. One of the limitations they note in their study design is the lack of matching to a control group for differences in baseline characteristics across the 3 exposure groups. Our study was designed to compare those with OCS exposure with a control group without exposure and used propensity scores to match baseline characteristics across cohorts. As discussed above, matching is important to address potential selection bias in observational research. Our study also used a different definition of exposure based on the number of prescriptions within a year. This was meant to capture both short-term OCS bursts and continuous/chronic OCS use for uncontrolled asthma. Their definition of exposure is more likely to capture continuous/chronic OCS use for longer duration.
The inclusion criteria of the 2 studies were also significantly different. Lefebvre et al 5 required the use of at least 6 months of continuous OCS before study inclusion, whereas our study excluded those with prior OCS exposure (washout) for 12 months before inclusion. This likely makes our sample more reflective of new incident OCS use and less severe asthma (or at least new-onset severe asthma) and more likely to include those newly exposed to OCS. In addition, their inclusion requirement of 6 months of continuous OCS use might result in a population more likely to include severe patients taking continuous OCSs and exclude those on burst therapy. Our study was designed to exclude the confounding effects of prior OCS exposure to examine the direct association of exposure with the longitudinal development of future AEs.
The study by Lefebvre et al 5 was conducted in a Medicaid population of 6 states, whereas our study population (MarketScan) was more reflective of a managed care population across the United States. Lefebvre et al provide important insight into the relationship between OCS exposure and AEs. The sample characteristics, study design, and exclusion criteria (Medicaid; chronic OCS use) make the results of Lefebvre et al generalizable to a different population (more severe sicker patients with a history of chronic OCS use). Our study examined a unique classification of OCS exposure, comparing those taking 4 or more prescriptions of OCSs per year with those without OCS exposure (and lower levels of exposure: 1-3 prescriptions per year). This method of quantifying OCS exposure has clinical practice and future research advantages compared with other approaches. It is relatively easy to ascertain the number of OCS prescriptions used in a given year, irrespective of whether through discussions with patients, questionnaires, chart reviews, or examination of administrative/claims data. This measure of exposure is also relevant in asthmatic patients because it can be meaningful to capture exposure from continuous use or sporadic bursts of OCS therapy. Other more granular measures, such as cumulative annual/monthly dose, daily dose, or average dose of milligram of prednisone equivalence, might be more informative but are more challenging to ascertain. A comparison of our chosen definition of exposure with these other more granular approaches would be very informative for future research but is beyond the scope of the current manuscript.
The results of this research are novel because they suggest an association between OCS use and AEs using an easily replicable measure of exposure that might reflect either continuous or sporadic OCS exposure. The results provide preliminary evidence that suggest that using 4 or more OCS prescriptions per year is associated with deleterious AEs regardless of dose or duration or whether it is continuous or sporadic use.
OCSs are available in generic formulations with extremely low costs. In addition, they are very effective for asthma exacerbations. OCSs are commonly used for severe asthma. This research provides additional information about the possible link between OCS use and AEs. Previous research has shown that OCS use results in increased health care costs, 7 likely mediated by the development of AEs. Although alternative treatments exist (eg, omalizumab, mepolizumab, reslizumab, and many others in the pipeline), they are rarely used because of payer cost-containment strategies. More research is needed to better understand the true cost of OCS use and how it compares with treatment alternatives. In addition, clinicians need to be aware of the risks associated with OCS use and discuss the benefit and risk tradeoffs with their patients.
Although the combined end point was the primary outcome of interest, it is interesting to note the associations of OCS exposure with individual AEs. Some of the individual AE analyses might not have had adequate power to assess significant associations with OCS exposure. Table E3 in this article's Online Repository at www.jacionline.org shows that the number of subjects with exposure to 4 or more prescriptions of OCSs was very small for some AEs. However, it is also possible that these individual AEs were not associated with OCS use. In addition, some of the AEs might require longer duration or higher dose exposure than was captured in this study.
There are limitations of this research. This was an observational study and cannot be interpreted as evidence of causation but rather only association. It is possible that patients receiving OCSs are given more vigilant screening for certain AEs (eg, osteoporosis). This could influence the detection rate of certain AEs. However, the association between OCS exposure and AEs was strong, even among AEs that are unlikely to be subject to screening vigilance (eg, fractures). In addition, the definition of OCS exposure did not include other potentially important measures, such as cumulative annual/monthly dose, daily dose, or average dose. The relative rarity of the use of OCSs and the scarcity of outcomes (AEs) results in the need for an observational study design with a very large sample. However, observational studies are susceptible to selection bias. Patients who end up being treated with OCSs are much sicker than those who do not independent of the harm done by actual exposure to OCSs (ie, they have underlying characteristics and health that make them much more likely to be sick and to have AEs). Our methodological approach was designed to mitigate this potential selection bias by using propensity score matching of baseline characteristics indicative of poor asthma control and severity, general poor health, and comorbidity burden. Table II suggests that the samples were similar across observable characteristics after matching. In addition, the cohorts did not have statistically significant differences in the percentage of subjects using prescription drugs for autoimmune indications, rheumatoid arthritis (0.33%; 0.39%), Crohn disease (0.17%; 0.19%), lupus (0.15%; 0.17%), or multiple sclerosis (0.17%; 0.19%; all P > .05). Confounding variables were directly adjusted in the analyses (age, sex, geographic region, years of follow-up, insurance type, use of non-OCS immunosuppressive medications, and general comorbidity burden). Adjusting for confounding variables directly in the statistical analyses might also have helped reduce bias. However, it is possible that the cohorts differed by other conditions that require the use of OCSs or increase the likelihood of AEs. By nature of needing OCSs, the patients in the OCS cohort likely had more severe asthma than those in the no OCS cohort. It is possible that underlying asthma severity confounds the relationship with AEs.
A potential limitation to our study design relates to ICS exposure. It is possible that long-term exposure to ICSs or high-dose ICSs confounds the relationship between OCS and AEs. To appropriately address this potential, we reviewed the published literature to understand how to best incorporate ICS exposure into the analysis. Recently published research of OCS exposure and AEs in asthmatic patients has not controlled for ICS or ICS dose. 5 In addition, previously published evidence in patients with other diseases has not controlled for possible ICS exposure. It is also unclear from the published literature which OCS-related AEs are significantly associated with ICS exposure. Previous research has not shown a consistent statistically significant association between ICS use and most of the OCS-related AEs included in our study, [13] [14] [15] [16] but other AEs not included in our study were significant (eg, thrush). 13 We relied heavily on previously published research to identify the select AEs that have been shown to have a statistically significant association with OCS use in our study design. Future research considering this issue might need to reconsider which OCS-related AEs should be expected to be associated with ICS exposure and whether additional ICS-related AEs should be included.
To examine how ICS exposure might modify or confound the relationship with OCS-related AEs, we conducted 2 additional sensitivity analyses. First, we controlled for any exposure to ICSs (yes or no) in all analyses. Second, we controlled for the number of years in which the patient had used ICSs in the past (a count variable indicating the total number of years of previous ICS use). The results of both analyses showed a negligible change in the coefficients and no change in the statistical significance of the OCS exposure variables, suggesting no confounding effect of ICS exposure as included (see Tables E4-E6 in this article's Online Repository at www.jacionline.org). However, results showed that ICS use and the number of years of prior exposure to ICSs resulted in a lower odds ratio of having OCS-related AEs (odds ratio, 0.95 [P < .001] and 0.97 [P < .001], respectively). Interpretation of these with respect to ICS exposure is unclear. These results suggest the need for a much more sophisticated analysis of the relationship between ICS use and OCS-related AEs. For example, it might be important to specifically delineate the dose of ICS or cumulative exposure. Lower doses might be AE sparing and higher doses might be associated with AEs, or higher-dose ICSs might obviate the need for OCSs and consequently reduce OCS-related AEs. All of these hypotheses would need to be tested in a more specific study. It could also be important to specifically quantify the number of prescriptions, as we have done for the OCS exposure variables (although this would not correlate with an established clinical practice, such as OCS burst therapy). Comprehensively addressing the relationship between ICS exposure and OCS-related AEs is beyond the scope of the current article.
In addition, our analysis matched the cohorts based on asthma severity and control. Differential ICS exposure would only threaten the validity of the results if there was greater exposure to ICSs/high-dose ICSs in the OCS cohort compared with the no OCS cohort. The propensity score matching method used to balance the cohorts at baseline might have mitigated any differences in ICS/high-dose ICS exposure between the cohorts. This is particularly true because the cohorts were matched by asthma control and severity, and high-dose ICSs likely correlate to more severe and poorly controlled asthma. Nonetheless, this remains a potential limitation of this study. Additional future research on this topic is important.
The index date for the OCS cohort was determined based on the first OCS prescription. Determining an index date for the no OCS cohort was more challenging. Because of the necessity of artificially assigning a random index date for the no OCS cohort that retained a baseline and maximum follow-up, the number of years of follow-up data was higher for the no OCS cohort (see Table E2 ). However, all statistical analyses directly adjusted for the number of years of follow-up. Although this should control for any differences attributable to longer follow-up, potential exists that the samples were different in ways that were unobservable, and results should be interpreted with caution.
There are also inherent limitations in using claims data. In some cases AEs might be underreported because of patients not seeking medical attention or the AE being a secondary effect that was discussed but not coded. In some cases patients might have filled a prescription but not actually taken it. In addition, physicians might prescribe an amount of OCSs for several bursts to be used for future exacerbations. Although this could represent several burst exposures, our analysis would be limited to observing only 1 prescription. These idiosyncrasies can cause biased results. In addition, the use of 4 or more OCS prescriptions within the year as the main measure of exposure has limitations. There could be potential for variation in actual exposure to OCSs. For example, in the most extreme case, one prescription could be for 90 days of treatment.
In this case 4 prescriptions could reflect continuous exposure at any possible dose. One prescription might also reflect only 5 or 10 days of exposure, which would more likely reflect burst therapy.
Despite these limitations, this research provides new information about the association between the number of prescriptions for OCSs and the development of AEs. The results appear to suggest that each prescription for OCSs can result in a cumulative burden on current and future health, regardless of dose and duration, suggesting that even OCS bursts might be deleterious to health.
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Clinical implications: Short-term OCS bursts can result in long-term AEs. The index date was the date of the first OCS prescription for the OCS cohort. For the no OCS cohort, the index date was randomly assigned. The index date was required to fall between the 12th and 24th months of data capture for the subjects to ensure adequate follow-up for the no OCS cohort. This allowed for 12 months of baseline data before the index date and maximum follow-up data. 
